TP53 and colorectal carcinoma: Our study identified that p53 was activated upon CTD treatment to execute its anticancer activity via the AKT/MDM2/p53 pathway and that CTD suppresses the proliferation of human CRC cells by inhibiting MDM2-mediated p53 ubiquitination and degradation by targeting AKT to some extent.